2025年6月16日
“We continue to invest in the Phoenix platform to support the complex modeling needs of PK/PD scientists who rely on Phoenix for decision making,” said Martin Snyder, President, Data Science Software. “From the first non-compartmental analysis to safety assessment for millions of patients, Phoenix is a critical system throughout drug development.”
“Our Phoenix roadmap over the next year is groundbreaking,” said Snyder . “Our user community has asked for greater control to create, customize, and collaborate on the data visualizations that make up much of the Tables, Listings, and Figures section of submission documents. Later this year, they’ll have that ability with TFL Studio, the first module of the Phoenix Cloud.”
Certara（サターラ）について
サターラは、モデリング＆シミュレーション・ソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。製薬、教育機関、規制当局のお客様 2,400人以上、70ヵ国にてサターラの技術やサービスが活用されています。Learn more at www.certara.com.
サターラの問い合わせ先
Sheila Rocchio
[email protected]
報道機関の皆様：
赤津笑美 (emi.akatsu@certara.com)
[email protected]
関連コンテンツ
